The french spin-off PDC*line Pharma set at the GIGA
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens.
PDC*mel, our first drug candidate is currently in phase 1 clinical trials for melanoma. PDC*lung is in preclinical development for lung cancer.
Our approach can be applied to virtually any type of cancer and any patient population, and combined with differents cancer treatments.
PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia.
Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.
Foundation of PDC line Pharma SA, Belgium holding based in Liège (Belgium), headed by Eric Halioua, President & CEO.
ATMP classification granted by EMA for PDC*vac class of active immunotherapies for cancer
2015 Life Sciences Grand Prize of the French start-up competition Tremplin Entreprises
Exclusive licensing rights from the French Blood Bank (EFS)
Award of “Réseau Entreprendre”
Dr Isabelle Tabah-Fisch joins PDC*line Pharma as Chief Medical Officer
Laureate of the Worldwide Innovation Challenge 2030
Laureate of the i-LAB French national competition for the creation of innovative technologies companies
Foundation of PDC*line Pharma
GATE1 Grenoble incubator award winner
Start of the phase 1 first-in-man clinical trial in melanoma